Boehringer Ingelheim Ltd and Eli Lilly and Co. would like to inform you of a licence extension for Jentadueto (linagliptin/metformin) 2.5/850mg and 2.5/1000mg for use in combination with insulin. Jentadueto is indicated for the treatment of adults with type 2 diabetes mellitus, a) as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin, b) in combination with a sulphonylurea as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea, c) in combination with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.
For more information on Jentadueto, please contact Boehringer Ingelheim Ltd on +44 (1344) 742579 or email medinfo.bra@boehringer-ingelheim.com.